Novel Drug Delivery Systems Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Novel drug delivery system (NDDS) provides a therapeutic amount of drug to the specific site in the body to accomplish promptly and then maintain the desired drug concentration. The drug- delivery system should deliver drug at a rate control by the necessity of the body over a specified term of treatment. The novel drug delivery technologies enable to formulate the novel drug delivery devices by incorporating the drug molecules into new delivery systems, thus providing numerous therapeutic and commercial advantages.

Novel Drug Delivery Systems(NDDS) Market Segments Size & Growth:

Novel Drug Delivery Systems Market size is projected to reach approximately $294 billion by the end of 2024 with a CAGR of close to 8.9% from $178 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Increase in individual therapy, Requirement of controlled release of drugs, Increasing understanding of drug metabolism per individual and so on. However, Competition, Product Recalls, Stringent Regulatory Guidelines, Stability issues are thereby hampering the market growth.

Novel Drug Delivery Systems(NDDS) Market Segments Share:

Novel drug delivery systems(NDDS) market is categorised into Route of Administration which comprises of Transdermal drug delivery systems, Pulmonary drug delivery systems, Injectable drug delivery systems, Oral drug delivery systems and so on. Among the Route of Administration, Injectable drug delivery systems segment dominated the Biopharmaceuticals market in 2018. On the basis of Geography, North America is projected to eclipse the Novel drug delivery systems(NDDS) market and the growth in the North America economies is mainly attributed because of high disposable income, increasing research and development activities associated with development of drug delivery systems, high adoption rate of novel technologies and supportive reimbursement policies.

Novel Drug Delivery Systems(NDDS) Market Trends:

• GlaxoSmithKline and Chroma Therapeutics Limited announced a collaboration to develop Novel macrophage-targeted compounds using Chroma’s proprietary esterase-sensitive motif (ESM) technology, which adds amino acid esters to compounds with the aim of targeting the compounds to specific cells in the inflammatory disease process.
• Sanofi and Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimise development and commercialisation of specific products for the treatment of rare genetic diseases. Specifically:

Novel Drug Delivery Systems(NDDS) Market Research Report:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
• Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• The primary market players, such as
• Genzyme Corporation
• GlaxoSmithKline PLC
• Generex Biotechnology Corporation
• Genentech Inc.
• Johnson & Johnson